Evidence map›Paper›PMID 34650922›Full record

ArticleFrontiers in oncology2021

Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG 14300).

Stefania Russo, Rosalinda Ricotti, Silvia Molinelli, Filippo Patti, Amelia Barcellini, Edoardo Mastella, Andrea Pella, Chiara Paganelli, Giulia Marvaso, Matteo Pepa and 13 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Stefania RussoMedical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Rosalinda RicottiBioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Silvia MolinelliMedical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Filippo PattiRadiotherapy Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Amelia BarcelliniRadiotherapy Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Edoardo MastellaMedical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Andrea PellaBioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Chiara PaganelliDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Giulia MarvasoDivision of Radiotherapy, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Matteo PepaDivision of Radiotherapy, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Stefania ComiMedical Physics Unit, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Mattia ZaffaroniDivision of Radiotherapy, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Barbara AvuzziDepartment of Radiation Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Tommaso GiandiniMedical Physics Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Emanuele PignoliMedical Physics Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Riccardo ValdagniDepartment of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
Guido BaroniBioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Federica CattaniMedical Physics Unit, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Mario CioccaMedical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Barbara Alicja Jereczek-FossaDivision of Radiotherapy, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Ester OrlandiRadiotherapy Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Roberto OrecchiaScientific Directorate, IEO, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Barbara VischioniRadiotherapy Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
National Center for Oncological Hadrontherapy · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversity of Milan · ITEuropean Institute of Oncology · ITPolitecnico di Milano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rectum and bladder volumes play an important role in the dose distribution reproducibility in prostate cancer adenocarcinoma (PCa) radiotherapy, especially for particle therapy, where density variation can strongly affect the dose distribution. We investigated the reliability and reproducibility of our image-guided radiotherapy (IGRT) and treatment planning protocol for carbon ion radiotherapy (CIRT) within the phase II mixed beam study (AIRC IG 14300) for the treatment of high-risk PCa. In order to calculate the daily dose distribution, a set of synthetic computed tomography (sCT) images was generated from the cone beam computed tomography (CBCT) images acquired in each treatment session. Planning target volume (PTV) together with rectum and bladder volume variation was evaluated with sCT dose-volume histogram (DVH) metric deviations from the planning values. The correlations between the bladder and rectum volumes, and the corresponding DVH metrics, were also assessed. No significant difference in the bladder, rectum, and PTV median volumes between the planning computed tomography (pCT) and the sCT was found. In addition, no significant difference was assessed when comparing the average DVHs and median DVH metrics between pCT and sCT. Dose deviations determined by bladder and rectum filling variations demonstrated that dose distributions were reproducible in terms of both target coverage and organs at risk (OARs) sparing.

Indexed as

carbon ion radiotherapy (CIRT)deformable image registration (DIR)dose-of-the-day calculationhigh-risk prostate cancerimage-guided radiotherapy (IGRT)inter-fraction anatomical changes

Identifiers

PMID34650922
PMCPMC8506150
OpenAlexW3203834563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.